Skip to content

Author

Masayuki Takeda

1 paper indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Sep 2026

Reversible osimertinib‑associated heart failure mimicking cancer recurrence in EGFR ‑mutated non‑small cell lung cancer after pneumonectomy: A case report

. Osimertinib is a third‑generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor widely used in patients with EGFR mutation‑positive non‑small cell lung cancer (NSCLC). Although generally well tolerated, clinically notable cardiovascular toxicities, including heart failure, have been recognized. Th...

Hirona Yokoyama, N. Hara, R. Sasaki et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.